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ABSTRACT 
Introduction 
Within the past decade, community-associated methicillin-resistant 
Staphylococcus aureus (CA-MRSA) infection has become a major health concern. In 
human epidermal keratinocytes, S. aureus is mainly recognized through the pattern 
recognition receptor toll-like receptor 2 (TLR2) and its co-receptor, cluster of 
differentiation 14 (CD14). Cell components or secreted factors from S. aureus likely 
augment the virulence of CA-MRSA by directly suppressing keratinocyte innate immune 
responses. High mobility group box 1 (HMGB1) is actively released from eukaryotic 
cells during infection and can then directly bind to TLR2 to induce inflammation. We 
hypothesize that live CA-MRSA bacterial isolates cause recurrent infections in the skin 
by interrupting TLR2-mediated inflammation in keratinocytes to a greater extent than 
non-recurrent community-associated methicillin-sensitive Staphylococcus aureus (CA-
MSSA) isolates. 
Methods 
We asked if recurrent CA-MRSA isolates evade human innate immune responses 
in the skin by suppressing TLR2-mediated pro-inflammatory cytokine secretion by 
keratinocytes in vitro. We compared the effects of secreted factor exposure and live 
infection with recurrent CA-MRSA isolates to the effects of non-recurrent CA-MSSA on 
different components of the TLR2 signaling pathway in keratinocytes. A human 
  xi
immortalized keratinocyte cell line (HaCats) was stimulated with bacterial culture 
supernatants or live bacterial isolates for 6 hours. Post infection cell culture supernatants 
were subjected to ELISA to assess the secretion of pro-inflammatory and anti-
inflammatory cytokines. Total protein was also extracted from cell lysates post infection 
and subjected to Western Blot to assess relative protein levels of TLR2 and CD14, as 
well as for the activation and phosphorylation of NFκB.  
Results  
Exposure to bacterial culture supernatants from recurrent CA-MRSA isolates 
resulted in a significant decrease in pro-inflammatory and anti-inflammatory cytokine 
and HMGB1 secretion from keratinocytes. Interestingly, live infection of keratinocytes 
with recurrent CA-MRSA isolates only revealed a significant decrease in the secretion of 
the pro-inflammatory cytokine IL8 by keratinocytes post infection. There were no 
significant changes in pro-inflammatory TNFα, anti-inflammatory IL10, or HMGB1 
secretion from cells post infection. Additionally, no significant changes in overall 
cytokine secretion were observed from keratinocytes treated with live recurrent CA-
MRSA isolates obtained during subsequent infections of the same patient. Recurrent CA-
MRSA live infection also did not result in any significant changes in surface receptor 
(TLR2 or CD14) expression 6 hours post infection or NFκB activation 15 minutes post 
infection in our system.  
Conclusions  
We conclude that, under our experimental conditions, recurrent CA-MRSA 
bacterial isolates do not suppress TLR2-mediated pro-inflammatory cytokine secretion by 
  xii
keratinocytes by means of cell surface virulence factors. Based on our findings, it is more 
likely that recurrent CA-MRSA isolates may utilize a secreted virulence factor(s) to cause 
recurrent infection. This effect could then perhaps cause a decrease in recognition of the 
pathogen by TLR2 and the host immune system. It is important to further our 
understanding of the interactions between recurrent bacterial isolates and the human 
innate immune response in order to develop improved treatment and management for this 
pathology.
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CHAPTER ONE 
INTRODUCTION 
Within the past decade, the incidence of community-associated methicillin-
resistant Staphylococcus aureus (CA-MRSA) infections in otherwise healthy individuals 
has increased and has become a major health concern. The increasing frequency of these 
infections demonstrates the importance of gaining a better understanding of the 
pathogenesis of CA-MRSA skin infection in order to progress development of novel 
treatment regimens. 
S. aureus is a rapidly adapting organism that utilizes a number of different 
secreted and cell surface virulence factors to evade host defenses (4, 6, 7, 45). S. aureus 
is recognized by Toll-like receptor 2 (TLR2), a major cell surface receptor present on a 
variety of human cell types, including keratinocytes. TLR2 requires interaction with one 
of its co-receptors (TLR1/TLR6/cluster of differentiation 14 (CD14)), ultimately 
resulting in an increase in the innate inflammatory response to infection via intracellular 
nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) signaling (6). 
TLR2 stimulation and production of pro-inflammatory cytokines can additionally lead to 
the release of high-mobility-group box 1 (HMGB1) (19). Under normal cellular 
conditions, HMGB1 acts as a DNA-binding protein and transcription factor. Under 
inflammatory conditions, such as IL6 and TNFα production, this protein can be 
translocated from the nucleus to the extracellular space, where it can then bind TLR2 
2 
 
(13). This binding interaction initiates further TLR2-mediated inflammatory responses 
(13) including the secretion of  pro-inflammatory (IL6, IL8 and TNFα) and anti-
inflammatory (IL10) cytokines by keratinocytes.  
We hypothesize that recurrent CA-MRSA isolates evade human innate immune 
responses in the skin by suppressing TLR2-mediated pro-inflammatory cytokine 
secretion by keratinocytes. It is possible that patients with recurrent CA-MRSA infections 
are colonized with bacterial isolates that possess or upregulate specific virulence factors 
to evade host defenses. This would facilitate the increase in pathogenicity and frequency 
of recurrence seen with CA-MRSA isolates. We used the secretion of these cytokines 
post infection as an indication of the TLR2-mediated inflammatory responses during 
keratinocyte infection in vitro. In all experiments, we compared the effects of recurrent 
CA-MRSA infection of keratinocytes relative to the effects of non-recurrent CA-MSSA 
and non-recurrent CA-MRSA isolates on downstream TLR2 signaling events in 
keratinocytes. The goal of this project was to identify possible mechanisms by which 
recurrent CA-MRSA isolates can evade keratinocyte innate immune responses, leading to 
their increased pathogenicity, relative to non-recurrent CA-MSSA isolates, and their 
increased ability to cause recurrent infection. 
 
Overall Hypothesis 
Recurrent CA-MRSA isolates evade human innate immune responses in the skin by 
suppressing TLR2-mediated pro-inflammatory cytokine secretion by keratinocytes post 
infection. 
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Specific Aims 
Aim 1: Establish whether recurrent CA-MRSA isolates inhibit key interactions between 
TLR2 and its co-receptors or downstream intracellular NFκB signaling necessary for pro-
inflammatory cytokine production to a greater degree than non-recurrent CA-MSSA 
isolates using an in vitro model of S. aureus infection in a keratinocyte cell line (HaCats). 
Rationale: In preliminary experiments, exposure of normal epidermal keratinocytes 
(NHEKs) to recurrent CA-MRSA bacterial culture supernatants exhibited less relative 
pro-inflammatory (IL6, IL8 and TNFα) and anti-inflammatory (IL10) cytokine secretion 
from keratinocytes than cells that were exposed to MSSA bacterial culture supernatants. 
Secretion of these cytokines is at least partially mediated by the TLR2 signaling pathway. 
Since TLR2 is the main recognition receptor of S. aureus, perturbations in this pathway 
could suppress the innate immune response to infection resulting in decreased recognition 
of the pathogen and therefore, increased pathogenicity of the bacteria. 
Hypothesis I: Recurrent CA-MRSA isolates inhibit the binding between TLR2 and 
its co-receptors, and reduce downstream NFκB activation or translocation as a 
mechanism to reduce pro-inflammatory cytokine secretion from keratinocytes. 
To test this hypothesis, we will: 
Aim 1a: Assess the ability of recurrent CA-MRSA clinical isolates to inhibit the 
protein-protein interactions between TLR2 and its co-receptors (TLR1/TLR6/CD14), 
a binding interaction that is required for TLR2-mediated pro-inflammatory cytokine 
secretion post infection. 
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Rationale: TLR2 requires recruitment and binding of co-receptors for activation. This 
leads to the translocation of NFκB into the nucleus where it binds DNA and effects 
gene transcription, including transcription of pro-inflammatory genes. 
 
Aim 1b: Establish whether recurrent CA-MRSA isolates inhibit NFκB translocation 
from the cytoplasm to the nucleus or activation via phosphorylation, resulting in a 
decrease in downstream TLR2-mediated pro-inflammatory cytokine release. 
Rationale: NFκB translocation from the cytoplasm to the nucleus and nuclear 
activation via phosphorylation are required for transcription of downstream TLR2-
mediated cytokines. 
 
Aim 2: Assess whether recurrent CA-MRSA isolates disrupt HMGB1-DNA binding 
interactions at pro-inflammatory cytokine gene promoters, inhibit HMGB1 translocation 
from the nucleus to the extracellular space, or hinder extracellular HMGB1/TLR2 
binding to a greater degree than non-recurrent CA-MSSA, as mechanisms to decrease 
TLR2 mediated pro-inflammatory secretion from keratinocytes. 
Rationale: HMGB1 is a multifunctional protein that acts as a DNA binding protein that 
can be translocated from the nucleus to the extracellular space during infection. In the 
extracellular space, it can bind and activate TLR2 to further progress the secretion of pro-
inflammatory cytokines. Thus, recurrent CA-MRSA isolates may have evolved 
mechanisms to impair HMGB1 localization or function in keratinocytes as a mechanism 
to enhance pathogenicity. 
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Hypothesis II: Recurrent CA-MRSA isolates reduce HMGB1 secretion and 
HMGB1 binding to TLR2 as a mechanism to reduce pro-inflammatory cytokine 
secretion by keratinocytes. 
To test this hypothesis we will: 
Aim 2a: Evaluate the ability of recurrent CA-MRSA isolates to disrupt the binding of 
HMGB1 to the promoter regions of genes that encode pro-inflammatory cytokines 
induced by TLR2 activation. 
Rationale: HMGB1 is a nuclear DNA binding protein that is able to bind gene 
segments encoding pro-inflammatory cytokines, resulting in decreased pro-
inflammatory cytokine gene transcription. 
 
Aim 2b: Establish whether recurrent CA-MRSA isolates alter the translocation of 
HMGB1 from the nucleus to the extracellular space during infection. 
Rationale: HMGB1 is normally present in the nucleus but can be translocated to the 
extracellular space in response to infection. In the extracellular space, HMGB1 can 
bind TLR2 on the cellular surface to further progress the inflammatory response and 
therefore, increase the production of pro-inflammatory cytokines. 
 
Aim 2c: Assess whether recurrent CA-MRSA isolates inhibit the protein-protein 
binding between TLR2 and HMGB1, and to determine if the addition of exogenous 
HMGB1 can reverse the suppression of TLR2-mediated pro-inflammatory cytokine 
production. 
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Rationale: HMGB1 is translocated to the extracellular space post infection where it 
binds TLR2 to further progress the inflammatory response and therefore, pro-
inflammatory cytokine production. 
 
Impact: These studies will further our understanding of how CA-MRSA bacteria are able 
to interact with the human host innate immune system in the skin in order to cause 
recurrent infection in otherwise healthy individuals. For the first time, we investigated the 
innate evasion mechanisms not only of recurrent CA-MRSA clinical isolates between 
patients, but also within the same patient during subsequent recurrences. This study also 
provides a novel look at the role of HMGB1 during skin infection. It is known that 
HMGB1 is secreted by activated macrophages and monocytes after injury or infection 
and that HMGB1 in the skin can facilitate wound healing (81) and cell migration (82). In 
the context of skin infection specifically, the involvement and mechanism of this protein 
remains unexplored. Understanding these mechanisms will allow us to create better and 
more specific targets for drug therapies, and will potentially alter the way that we 
currently treat recurrent CA-MRSA infections. CA-MRSA is a growing epidemic. 
Though there have been studies done looking at CA-MRSA, many of them are genomic 
(3, 68) or epidemiologic (49, 51, 54) in nature. This study provides the first look at 
possible alterations in the TLR2 signaling pathway in keratinocytes as well as in the 
localization or function of HMGB1 in the skin to explain the increased virulence of 
recurrent CA-MRSA bacteria. 
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CHAPTER TWO 
INTRODUCTION – LITERATURE REVIEW 
 
Staphylococcus aureus as a prominent human pathogen 
Infections caused by Staphylococcus aureus are very important healthcare issues 
that are increasing in number and severity resulting in increasing morbidity and mortality 
of patients (70). In the United States in 2003 alone, 11 million doctor’s office visits and 
over 400,000 inpatient admissions were reported to be due to S. aureus skin infections 
(52). These numbers are further increasing due to the emergence of antibiotic resistant 
strains. Methicillin-resistant Staphylococcus aureus (MRSA) infections are estimated to 
kill about 20,000 hospitalized patients in America each year (53). In 2005 there were an 
estimated 94,360 invasive diseases and 18,650 deaths due to MRSA in the US alone, 
which is more than HIV (4). These statistics are rising due to the emergence of more 
pathogenic community associated MRSA (CA-MRSA) isolates. These facts demonstrate 
the importance of gaining a better understanding of the pathogenesis of CA-MRSA skin 
infection in order to take steps toward developing novel treatment regimens. 
Approximately one third of the human population is colonized with S aureus (15), 
but in most cases, these pathogens are commensal and do not cause invasive disease. In 
other individuals, S. aureus can be responsible for life threatening infections in several 
tissues. Host colonization is the first step in the S. aureus infection process and usually 
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occurs through direct skin-to-skin contact with a colonized individual. Though this 
contact has been identified as a risk factor for colonization or infection, it does not 
correlate directly with colonization rates (51). The question then of course is, why do so 
few patients who are colonized with S. aureus develop infection? There have been a 
number of studies done on S. aureus virulence factors in attempt to identify a single 
virulence determinant responsible for this phenomenon (71, 72), but it is more likely that 
multiple factors are responsible.  
 
S. aureus and Disease 
S. aureus isolates are capable of producing a number of secreted and cell surface 
virulence factors that allow them to avoid host defenses in order to cause disease. 
Production of these virulence factors is temporally regulated by the bacteria and is 
dependent on environmental factors such as cell density and energy availability (4). 
Expression of the virulence genes in S. aureus occurs during very particular bacterial 
growth phases. For example, in early exponential phase, coagulase, protein A, 
fibronectin, and clumping factors A and B are expressed. Throughout the entire 
exponential phase, hyaluronidase, δ-hemolysin and entertoxin A are produced. Many of 
the other key virulence factors of S. aureus are expressed during post exponential phase 
(43). In general, cell surface virulence factors are expressed during exponential growth 
phase and secreted virulence factors are expressed during stationary phase (79). 
Some examples of staphylococcal secreted virulence factors are superantigens, 
proteases, and staphylococcal complement inhibitor (SCIN) (6). Superantigens can over-
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stimulate a T cell response and result in staphylococcal toxic shock syndrome. Bacterial 
proteases can cleave and inactivate antimicrobial peptides. SCIN binds and stabilizes 
convertases on the surface of the bacteria in order to inhibit all three complement 
pathways (6). There are also a number of bacterial cell surface virulence factors that have 
been identified in S. aureus. These include the presence of adherence proteins that bind 
and inhibit Intracellular Adhesion Molecule-1 (ICAM-1) in order to prevent leukocyte 
adhesion and diapedesis as part of the inflammatory response (6). There is also a known 
redundancy in the innate immune evasion factors of S. aureus (6, 7). This suggests that a 
single molecule or structure is not responsible for the increased virulence of CA-MRSA 
isolates. This increase in pathogenicity is more likely due to a network of factors, 
potentially involving both soluble bacterial derived proteins and cell surface components. 
 Strain-dependent effects relating to mastitis outcomes have also been specifically 
demonstrated, despite the close genetic relatedness between S. aureus strains tested (78). 
For example, there are four restriction modification systems in S. aureus that are known 
to be responsible for the ability of the bacteria to take up foreign DNA and to acquire 
mobile genetic elements. Particular strains with mutations in these systems are able to 
more effectively acquire foreign DNA or mobile genetic elements leading to rapid 
acquisition of virulence genes and therefore, enhanced virulence (78).  
 
The Emergence of CA-MRSA as a Public Health Concern 
Methicillin resistant Staphylococcus aureus (MRSA) first emerged as a public 
health concern in the early 1960s, at which time it was mostly encountered in a healthcare 
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setting and affected patients with known immune deficiencies (7). MRSA was first 
reported just two years after the introduction of methicillin as a treatment for S. aureus 
infection (2), indicating a very high rate of antibiotic resistance acquisition of these 
bacteria (7). Within the past decade, community-associated MRSA (CA-MRSA) 
infection in patients with no previously identified risk factors has become a major and 
growing health concern. CA-MRSA first appeared in the early 1990s and has since 
become endemic in a number of countries, with the highest prevalence in the United 
States (7). CA-MRSA has most clearly been linked to situations and places where there is 
a high chance of skin disruption and close physical contact such as sports locker rooms or 
at daycare centers. The increasing numbers of infections and hospital visits due to CA-
MRSA also indicate the use of additional health care resources and additional cost to the 
patient (54). In one study, an economic simulation model estimated the annual burden of 
CA-MRSA infections alone to be between 1.4 billion to 13.8 billion dollars per year (55).  
CA-MRSA strains have been shown to have enhanced virulence compared to 
traditional hospital acquired (HA)-MRSA strains which rarely cause disease outside of 
the hospital setting (7). These strains are known to be genetically different from one 
another in the sizes of their large chromosome cassettes (SCCmec) (4). HA-MRSA 
isolates contain larger SCCmec cassettes than CA-MRSA and CA-MSSA isolates 
because they are resistant to a larger range of antibiotics (26).  
Additionally, differences in the production of secreted virulence factors by CA-
MRSA and those produced by HA-MRSA and CA-MSSA strains have been 
demonstrated (26). These investigators hypothesized that these differences were due to 
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the niche that the bacteria occupied within the host. Since HA-MRSA isolates contain 
larger SCCmec cassettes, this may require selection by the bacteria to produce only the 
secreted factors that are necessary for the survival of the organism in that particular 
environment. An example of this niche dependency is the lower production of toxic 
shock syndrome toxin 1 (TSST-1) exotoxin by S. aureus strains in the menstrual, vaginal 
mucosa relative to the levels of TSST-1 production by the same S. aureus strain isolated 
from the skin (26). This is due to the fact that this toxin is required for skin survival and 
causes a great amount of tissue destruction that would be detrimental to the vaginal 
mucosa, and therefore, bacterial propagation. Differences in the virulence factors secreted 
by CA-MRSA and CA-MSSA isolates have also been found. These investigators 
demonstrated that CA-MRSA isolates produce increased amounts of the secreted 
superantigenic virulence factors TSST-1 and Staphylococcal enterotoxin C (SEC) relative 
to their CA-MSSA counterparts in vitro (26). Though the clinical significance of this 
finding is currently unclear, it highlights the possibility that expression levels of virulence 
factors may play a role in the increased virulence of CA-MRSA isolates. 
Unfortunately, the clinical diagnosis of CA-MRSA is not well defined. At Loyola 
University Medical Center, CA-MRSA is classified as such if a MRSA infection is 
acquired 48 hours or less after hospital admission. If the infection is acquired after this 
time frame then the infection is classified as HA-MRSA. This diagnosis definition is 
problematic for a number of reasons. These reasons include the timing of bacterial 
cultures depending on clinical symptoms or the fact that S. aureus can colonize an 
individual up to years prior to symptomatic infection (29). Additionally, this definition 
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does not take any patient factors into account, such as chronic illness or recent antibiotic 
treatment. This means that by default, any other infection is classified as community-
associated, even if there are other underlying health complications that could have 
resulted in the infection. This definition needs to be further defined in order to better 
address clinical management of S. aureus infections. 
 
Innate Immunity and S. aureus 
S. aureus has evolved to become very effective at circumventing the host immune 
system. The interaction of S. aureus with the innate immune system is of particular 
interest because it acts as a first line of defense against pathogens in the body. The first 
barrier to bacterial infection is the skin. Epidermal keratinocytes make up the majority of 
the cells in the epidermis and are responsible for maintaining the physical barrier between 
the internal and external environments. In addition, keratinocytes encode genes for a 
number of immune modulators including cytokines, chemokines, and antimicrobial 
peptides that are upregulated during times of infection or cellular stress (83). 
There are a number of important microbial defense mechanisms in humans that 
are known to be essential for clearance of S. aureus including antimicrobial peptides 
(AMPs). AMPs are small cationic peptides that have broad spectrum antimicrobial 
activity and are secreted by a number of cell types, including keratinocytes. AMP 
dysregulation has been implicated in a number of inflammatory diseases, such as atopic 
dermatitis and psoriasis (18). Human skin keratinocytes secrete only low levels of AMPs 
under healthy conditions, but AMPs are robustly induced in keratinocytes after infection. 
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AMPs act as both a natural antibiotic and “alarmins” that further amplify the innate 
immune and wound healing responses (18). MRSA strains have even been found to have 
increased resistance to the active form of the human cathelicidin antimicrobial peptide 
(LL-37) relative to the resistance of this AMP by MSSA strains (12). It remains unclear 
whether patients with CA-MRSA infection are colonized with these AMP resistant 
strains.  
Another important molecule in the study of the interaction between S. aureus and 
the host innate immune system is IL-17 and its receptor, IL-17R. T helper 17 (Th) 17 
cells are recruited to the site of an infection after TLR2 activation and release of pro-
inflammatory cytokines such as IL-1α, IL-1β, IL-6 and IL-23 (14). Th17 cells also 
produce IL-17A and IL-17F which then bind the IL-17 receptor on the surface of 
keratinocytes, leading to the production of AMPs (14). Interestingly, it has been found 
that human keratinocytes and bronchial epithelial cells produce more AMPs and 
cytokines in response to IL17 as compared to other cell types, such as fibroblasts (65). 
This highlights the potential of IL17 to be used in therapies against skin and lung 
pathogens. 
S. aureus interacts with the host immune system through binding of cell wall 
lipoproteins to host cell surface receptor Toll-like receptor 2 (TLR2). This leads to the 
activation and translocation of the transcription factor, NFκB to the nucleus to induce an 
inflammatory response. TLR2, which is expressed by epidermal keratinocytes, has been 
found to be a very important receptor in S. aureus pathogenesis. It has been shown that 
mice deficient in TLR2 or myeloid differentiation primary response protein 88 (MyD88), 
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an adaptor protein required for downstream signaling of this receptor, are highly 
susceptible to infection by S. aureus (8). Therefore, CA-MRSA isolates may be able to 
cause recurrent infection by subverting the TLR2 recognition pathway in keratinocytes, 
leading to a decrease in downstream inflammation. 
 
The TLR2 Signaling Pathway and Skin Disease 
Toll-like receptors are a family of transmembrane proteins that act to recognize 
pathogenic stimuli in order to elicit appropriate inflammatory responses to infection. In 
humans, at least 10 different TLRs have been identified and most of them, with the 
exceptions of TLR3 and TLR4, signal through the MyD88 pathway which eventually 
triggers NFκB-dependent events (1). In human skin, S. aureus is mainly recognized by 
keratinocytes via TLR2, which also requires the recruitment and heterodimerization with 
co-receptors TLR1, TLR6 or CD14. Heterodimerization allows these receptors to detect a 
wider range of pathogenic targets. For example, TLR2 heterodimerizes with TLR6 to 
recognize diacylated lipopeptides, such as macrophage-activating lipopeptide 2 
(MALP2). TLR2 can also heterodimerize with TLR1 to recognize triacylated 
lipopeptides (9). This receptor then signals through the MyD88 signaling pathway, 
ultimately resulting in an increase in translocation of NFκB to the nucleus. NFκB 
activation results in production of pro-inflammatory cytokines, chemokines, 
antimicrobial peptides (AMPs), and adhesion molecules (6) (Figure 1).  
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Figure 1: Summary of TLR2-mediated innate inflammatory responses in 
keratinocytes. In human skin, S. aureus is mainly recognized through Toll-like receptor 
2 (TLR2) which becomes activated and signals by binding to its co-receptor, CD14 and 
acting through the MyD88 signaling pathway, ultimately resulting in an increase in 
translocation of NFκB to the nucleus. NFκB signaling results in production pro-
inflammatory cytokines, AMPs, chemokines and adhesion molecules (6).  
 
Alterations or deficiencies in different aspects of innate immunity, including 
TLR2-mediated mechanisms, are known to be associated with different inflammatory or 
infectious skin disease states. For example, patients with atopic dermatitis (AD) have 
been shown to exhibit significantly decreased numbers of TLR2+ peripheral blood 
mononuclear cells (PBMCs). This suggests that the deficiency of TLR2 in AD patients 
leads to disease pathogenesis (35). Additionally, the balance between pro-inflammatory 
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and anti-inflammatory cytokines is crucial to appropriate immune responses. If this 
balance is disrupted, it can lead to variable levels of inflammation that could be 
detrimental to the host during infection or disease and therefore, lead to increased 
symptoms. For example, significantly decreased levels of cutaneous IL10 mRNA 
expression have been identified in psoriasis patients (73). Administration of subcutaneous 
IL10 was effective in reducing symptoms of psoriasis in a small number of patients (73), 
suggesting that at least a subset of psoriasis symptoms are due to the absence of anti-
inflammatory cytokines. It is possible that recurrent CA-MRSA isolates are able to 
suppress the TLR2 signaling pathway, and therefore downstream pro-inflammatory and 
anti-inflammatory cytokine production, leading to an increase in inflammation, disease 
symptoms, and/or recurrence. 
 
HMGB1, Inflammation, and Disease 
TLR2 stimulation and production of pro-inflammatory cytokines can additionally 
lead to release of another nuclear protein, high-mobility-group box 1 (HMGB1). HMGB1 
is a ubiquitously expressed and highly conserved chromatin binding factor that acts in the 
nucleus to bend DNA and promote protein assembly during normal cellular conditions. 
The chromatin is altered by different acetylation patterns in order to allow for the binding 
of HMGB1; HMGB1 itself remains unaltered (13). Additionally, this protein is secreted 
by activated macrophages and monocytes under inflammatory conditions and is also 
known to be passively released from necrotic cells (13). Necrotic cells that are deficient 
in HMGB1 have a decreased ability to promote inflammation and mice with HMGB1 
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deficiency die within a few hours after birth (13). Apoptotic cells retain their HMGB1, 
while necrotic cells release it, which may be a safeguard for the body to prevent 
unnecessary inflammation (13). 
HMGB1 is able to bind either the receptor for advanced glycation endproducts 
(RAGE), TLR2 or TLR4 differentially between cell types in order to initiate further 
inflammatory pathways in a systemic manner (Figure 2). HMGB1 binding to RAGE is 
known to be involved in chemotaxis and cell migration, while interactions with TLR2 or 
TLR4 are known to be associated with increased cytokine production in response to 
cellular stimuli (41). HMGB1 activity is associated with the severity of inflammatory 
disease (1) and has been implicated in a number of severe inflammatory diseases 
including systemic lupus erythematosus (34), rheumatoid arthritis (31), and ankylosing 
spondylitis (33). Additionally, high levels of HMGB1 are detected in the circulation of 
patients with severe sepsis (42). These facts emphasize the importance of understanding 
the role of HMGB1 in the scope of the immune response to injury and infection. 
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Figure 2: Summary of HMGB1-mediated innate inflammatory responses in 
keratinocytes. TLR2 stimulation and production of pro-inflammatory cytokines can 
additionally lead to release of the nuclear protein, HMGB1, from late phase necrotic cells 
upon infection. HMGB1 is known to be a transcriptional regulator in the nucleus that 
affects the transcription of pro-inflammatory genes in part by NFκB signaling. HMGB1 
can be translocated to the cytoplasm and then to the extracellular space where it is then 
able to bind to TLR2 in order to initiate further inflammatory pathways in a systemic 
manner (1).  
 
MRSA Diagnosis and Treatment 
S. aureus infections were initially treated with penicillin and then by methicillin 
after penicillin resistance of these bacteria was identified. Just two years after methicillin 
began being used, MRSA was identified. MRSA is resistant to all β-lactam antibiotics. In 
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MSSA bacterial isolates, there are four penicillin-binding proteins (PBPs) that are 
inactivated in the presence of β-lactams. This causes cell death and inhibition of cell wall 
biosynthesis (3). MRSA strains have an extra PBP, with a low affinity for β-lactams, 
which retains its activity even in the presence of β-lactam drugs. This allows for cell wall 
biosynthesis to continue (3).  
Currently, MRSA (including CA-MRSA) infections are treated with a variety of 
other classes of antibiotics but are continuing to acquire resistance to these antibiotics as 
well. For example, heteroresistant vancomycin-intermediate S. aureus (hVISA) has 
become an increasing complication in the treatment of MRSA. This resistance pattern is 
mediated by the expression of a particular gene in some S. aureus strains that modifies 
the structure of the peptidoglycan. This modification causes a loss of affinity of 
vancomycin for the peptidoglycan precursor (1). Sub-curative doses of antibiotics are 
indicative of the antibiotic levels in a patient who does not follow a consistent treatment 
regimen. These antibiotic doses are known to cause clonal expansion of resistant bacteria 
in vivo. This allows them to out-compete antibiotic sensitive bacteria (50).  
Due to the fast acquisition of antibiotic resistance of S. aureus, a number of 
different approaches can be studied in order to find new possible treatments for the 
disease including immunomodulatory and vaccination strategies. One of the possible 
methods that have been suggested is the activation of TLR2 with an agonist to allow for 
increased inflammasome activation post infection (14). Another method could be to 
create an intranasal vaccine against Th17 cell-inducing S. aureus antigens to promote 
Th17 cell activity and Th17 mediated-cytokine production (14). Due to its rising 
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prevalence, it has become increasingly important to understand how CA-MRSA interacts 
with the host immune system. This understanding is crucial in being able to efficiently 
move toward administration of immune based therapies to treat S. aureus, including 
recurrent CA-MRSA infections. 
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CHAPTER THREE 
MATERIALS AND METHODS 
 
Bacterial preparation 
For all live infections, we used a protocol adapted from Kisich, et al (21). 
Bacterial isolates were grown overnight in 3 mL of tryptic soy broth (TSB) at 37ºC with 
shaking. The next day, 150 µl the bacterial overnight cultures were reinoculated into 3 
mL of new TSB media and grown up to a concentration of 1.0 x 10
8
 (colony forming 
units per milliliter) CFU/mL as determined by optical density (O.D) readings measured 
on a Spectromax spectrophotometer. Using a plate blank of TSB media and the path 
check function on, OD reads were taken until they were in the appropriate range of 0.75-
1.0. The target OD read was 0.75 which corresponds to a bacterial concentration of 
slightly over 1.0 x 10
8
 CFU/mL to allow for some loss of bacteria in subsequent wash 
steps. If the OD read was greater than 1.0, the bacteria were diluted appropriately with 
TSB until the read was in range. These bacteria were then diluted appropriately to an OD 
read of 0.75 and the final volume was brought up to 1 mL with additional TSB. These 
samples were then spun down at 4000 RPM for 10 minutes, media was decanted, and 1 
mL of sterile 1 X phosphate buffered saline (PBS) was added to each sample prior to a 
quick vortex. This cycle was repeated once more before finally resuspending the bacterial 
pellet is 1 mL of sterile high glucose, serum free, and antibiotic free Dulbecco’s Modified 
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Eagle Medium (DMEM) containing sodium pyruvate to give a final working stock with a 
concentration of approximately 1.0 x 10
8
 CFU/mL. These bacterial stocks were also 
serially diluted and plated onto tryptic soy agar (TSA) plates in order to back calculate 
the concentration of each isolate used in the experiments. 
HaCat cell preparation 
Human HaCat keratinocyte cells were grown up in DMEM with 10% fetal bovine 
serum (FBS) and 1x penicillin/streptomycin. The media was changed the day after 
splitting of the cells as well as every other day until they reached the appropriate level of 
confluency depending on the experiment. The night before treatment, the media was 
removed and all cells were washed twice with sterile 1X PBS and serum free and 
antibiotic free DMEM were then added in the appropriate volumes to the cells for use in 
experiments. 
HaCat cell live infection 
Appropriate volumes of 1.0 x 10
8
 CFU/mL stocks of each bacterial isolate were 
be added to the appropriate size cell culture dishes containing HaCat cells and serum free 
and antibiotic free DMEM for a final infecting concentration of 1.0 x 10
6
 CFU/ml and 
allowed to incubate for an assay dependent period of time at 37ºC and 5% CO2. 
Total protein isolation 
After the appropriate incubation time, all cell culture supernatants were removed 
and the cells were washed twice with sterile 1X PBS. Then an appropriate amount of 
radioimmunoprecipitation assay (RIPA) buffer + Triton X-100 + Pierce HALT 
protease/phosphotase inhibitor (Ca. No. 78443) were added to each cell culture dish to 
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lyse all cells. These plates were then kept at 20ºC prior to cell scraping to remove all cells 
from the cell culture plate. Sonication of all cellular contents was carried out for 10 
seconds to break up the cell membranes prior to collection of the cellular supernatant. 
BCA Protein Assay 
Total protein levels were determined in cell lysates by utilizing Pierce’s 
Bicinchoninic acid (BCA) protein assay kit (Ca. No. 23227) per the microplate procedure 
provided by the manufacturer. 25 µl of each unknown sample and bovine serum albumin 
(BSA) standard (working range 20-2000 ug/ml) were added to a clear 96-well microplate. 
Then 200 µl of alkaline working reagent containing BCA was added to each well to 
chelate the Cu+2 ions produced from the reduction of Cu+1 by protein in the alkaline 
media resulting in a purple color that can be read on a plate reader at 562 nm after 30 
minute incubation at 37C. 
LDH Cytotoxicity Assay 
Post infection cell culture supernatants were used to carry out a lactate 
dehydrogenase (LDH) cytotoxicity assay per manufacturer’s instructions (Abcam, Ca. 
No. ab65393) to assess the relative levels of cell death between treatment groups and a 
vehicle control at various time points between 2 and 24 hours post infection. 
Cytokine ELISAs 
Cell culture supernatants were collected after 6 hours, spun down at 16000g for 
10 minutes to remove any residual bacteria, and used to run ELISAs for the pro-
inflammatory cytokines IL6, IL8 and TNFα as well as for the anti-inflammatory cytokine 
IL10 using Peprotech ELISA kits per the manufacturer’s instructions. 
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HMGB1 ELISA 
Cell cultures supernatants were collected from cell culture dishes 6 hours post infection 
with recurrent CA-MRSA, CA-MSSA or control groups. These supernatants were then 
spun down at 16000g for 10 minutes to remove any residual bacteria and total protein 
was isolated and quantified via BCA protein assay (outlined above). Supernatants were 
then used to carry out Biotang’s HMGB1 ELISA (Ca. No. HU8317) to look at secreted 
HMGB1 from keratinocytes in culture between groups per the manufacturer’s 
instructions. 
Western Blots 
25-40 µg of protein was loaded to a 12% Tris-HCl gel and ran at 90 volts for 
about 1.5 hours. The gel was then transferred to a polyvinyl difluoride (PVDF) 
membrane via wet transfer using Biorad tris/glycine buffer + methanol for either 1 hour 
at room temperature at 100 mV or overnight at 4ºC at 90 mAMPs. The membranes were 
then blocked with either PBS + 0.05% Tween-20 (PBST) or TBS + 0.05% Tween-20 
(TSBT). Next, the membranes were probed with one of the following primary antibodies 
overnight in block buffer at 4ºC: Rabbit anti-human TLR2 (Abcam, ab108998) at 1:1000 
overnight in 5% milk in PBST, Mouse anti-human CD14 (Santa Cruz, UCH-M1) at 
1:1000 in 5%  milk in PBST, Rabbit anti-HMGB1 (Abcam, ab18256) at 1:1000 in 5% 
milk in PBST, Rabbit anti-NFκB (Cell Signaling, D14E12) at 1:000 in 5% BSA in TBST, 
Rabbit anti-phospho-NFκB (Cell Signaling, 93H1) at 1:1000 in 5% BSA in TBST, 
Mouse anti-β-actin (Santa Cruz, C4) at 1:1000 in 5% milk in PBST, Mouse anti-TATA 
binding protein (Millipore, 05-1531) at 1:1000 in 5% milk in PBST, Rabbit anti-TLR1 
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(Abcam, ab68153) at 1:1000 in 5% milk in PBST, or Mouse anti-phospho-IκB (Cell 
Signaling) at 1:1000 in 5% milk in TBST. 
Membranes were then washed 4 times with PBST and probed with an anti-rabbit 
or anti-mouse secondary antibody (Vector) as appropriate at a 1:5000 dilution in block 
buffer. The blot was then stripped and reprobed as necessary up to 3 times for each blot. 
Densitometry was done and all bands were normalized to a loading control in order to 
evaluate relative levels of target proteins between recurrent CA-MRSA, non-recurrent 
CA-MSSA or control treatment groups. 
TLR2 immunoprecipitation (IP) 
Total protein concentration in each sample was determined by a using a 
colormetric Pierce BCA assay as described above. For the IP procedure, we begin with 
~500 µg total protein. Pre-clearance of the samples with 1.5 µl of Rabbit IgG and 20 µl of 
protein A/G beads was utilized to remove any non-specific binding that may have 
occurred due to the use of the protein A/G beads. After 30 minutes on ice, these samples 
were be spun down at 12,000g for 5 mins at 4º C and the supernatants were transferred to 
a new tube for use in the experiments. The total protein was then assessed again in the 
same way and the maximal amount of protein from each sample was incubated with 
rabbit anti-human TLR2 antibody (EPNCIR133) at a concentration of 1:100 overnight at 
4ºC with rocking. The next day, 20 µl of protein A/G beads was added to each tube and 
incubated at 4ºC with rocking again for 1 hour. The samples were then spun down again 
at 17,000g for 5 mins at 4ºC prior to supernatant collection. The pellet containing the 
bead/antibody complex was washed twice with 1X PBS, resuspended in 3x protein 
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sample buffer, boiled for 5-10 minutes, and put on ice shortly. Appropriate samples were 
quick spun to pellet the agarose beads and the supernatant was loaded to a 12% Tric-HCl 
gel. The gel was transferred to a PVDF membrane via wet transfer at for either 1 hour at 
room temperature at 100 mV or overnight at 4ºC at 90 mAMPs. The membranes were 
then blocked with Easy Blot blocking buffer (GenTex) for 30 minutes at room 
temperature and then probed with Rabbit anti-human TLR2 at 1:1000 overnight in block 
buffer at 4ºC and probed with an anti-rabbit secondary antibody (Vector) at a 1:5000 
dilution in block buffer. The blot was then be stripped and reprobed for TLR2 co-
receptors (TLR1, TLR6 and CD14) subsequently to assess relative binding of TLR2 to its 
co-receptors between groups. Densitometry was done normalized to total TLR2 and a 
loading control in order to evaluate relative levels of TLR2 interaction with each of its 
co-receptors between recurrent CA-MRSA, non recurrent CA-MSSA or control treatment 
groups. 
Immunocytochemistry (ICC) 
            HaCat cells were grown up to ~60%  confluency in 8 well chamber slides and 
infected with different bacterial isolates in the same fashion as mentioned previously at a 
concentration of 10
6
 CFU/mL and incubated at 37ºC for 6 hours. Supernatants were then 
removed and cells were washed twice with 1x PBS and then washed six times with 500 
µl of 1x Dako wash buffer. The wash buffer was then removed and the cells were fixed to 
the slide in 500 µl of acetone for 15 minutes at RT with shaking. After removal of 
acetone, the cells were washed three more times with PBS for 5 minutes each and then 
incubated in 200 µl of 10% FBS for 30 minutes at RT with shaking. The FBS was then 
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removed and the primary antibodies were applied to the cells and kept at 4ºC overnight 
with shaking. The next day, the slides were washed six times with Dako wash buffer 
prior to incubation with a 1:500 dilution of the fluorescent secondary antibody (FITC 
conjugated secondary antibody for CD14 or TLR1 and a Cy3 conjugated secondary 
antibody for TLR2) for 1 hour at RT. The slides were then washed 3 more times with 
Dako wash buffer and then cover slips were mounted with ~40 µl of Prolong Gold (DAPI 
nuclear stain) and dried overnight. A species matched normal IgG was used as a negative 
control to make sure that there is no non-specific binding of the primary antibody 
resulting in background florescence. The slides were then imaged the next day on the 
Evos microscope. 
Nuclear/cytosolic protein isolation 
HaCat cells were incubated for an assay dependent time point with 1.0 x 10
6 
CFU/mL of bacteria diluted in serum free and antibiotic free DMEM. After incubation, 
the supernatant was removed and the cells were washed twice with 1x PBS prior to the 
addition of 500 mL of 1x PBS + 5 µl of HALT protease/phosphatase inhibitor to each cell 
culture dish. Then isolation of nuclear and cytosolic protein extracts was carried out using 
the NE-PER Nuclear and Cytoplasmic Extraction Reagents kit (Thermo Scientific Cat No 
78835) per the manufacturer’s instructions. 
Addition of exogenous HMGB1 
HaCat cells were infected in vitro and 10 ug/mL of exogenous HMGB1 was added at 
0 hours post infection with recurrent CA-MRSA or CA-MSSA strains and incubated for 
6 hours at 37ºC and 5% CO2. 
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Chromatin-immunoprecipitation assay (ChIP) 
HaCat cells were grown up to 90% confluence in a 100 mm cell culture dish in 8 
mL of DMEM media. Cells were trypsinized with 1 ml of trypsin and 9 ml of DMEM 
media added for a total volume of 10 mL. 275 µl of a 37% Formaldehyde solution was 
added and the samples were incubated for 15 minutes with rocking. 1 ml of 1.25 M 
glycine solution was added to stop the reaction prior to centrifugation at 1500 RPM for 5 
minutes at 4ºC. The pellet was then washed with 1 ml of ice-cold PBS and transferred to 
a small eppendorf tube and spun again at 1500 RPM for 5 minutes at 4ºC. The next day, 
500 µl of a cell lysis buffer with protease inhibitor was added to the pelleted cells and 
incubated on ice for 15 minutes with frequent vortexing. Samples were then centrifuged 
at 800 g at 4ºC for 5 minutes. The supernatant was removed and discarded and the pellet 
was resuspended in 500 µl of nuclear lysis buffer plus protease inhibitor. Samples were 
then sonicated five times at power output 4 for 10 seconds each pulse to produce DNA 
fragments between 200 bp and 1 kb in size with the majority of them around 500 bp. For 
each IP sample, 100 µl of chromatin were diluted in 900 µl of dilution buffer and protease 
inhibitor and pre-cleared with 60 µl of protein G agarose for 4ºC for 5-6 hours. The 
supernatant was collected via centrifugation and 10 µl saved as input for each sample. 
Either an IgG control or antibodies specific for pro-inflammatory genes along with 20 µl 
of magnetic beads was added to the remainder of the supernatant and incubated overnight 
at 4ºC with rotation. Samples were then spun down and put into a magnet that beads will 
attach to, the liquid was then removed and the complex was pelleted by brief 
centrifugation and washed sequentially with low salt buffer, high salt buffer, LiCl buffer 
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and TE buffer. Chromatin was then eluted from the beads with 100 µl of elution buffer 
(SDS, water and NaHCO3) and DNA-protein cross-links were reversed with 8 µl of 5M 
NaCl followed by 65ºC incubation for 2 hours followed by a 95ºC incubation for 10 
minutes prior to brining the samples to RT. The samples were placed on the magnet 
again, the supernatant was harvested and the beads were discarded. DNA purification was 
then carried out using an Ultraclean kit for DNA purification (Bioexpress #G-3148-250). 
DNA isolated was then analyzed by qPCR and all samples were normalized to the 
amount of input DNA. 
Statistical Analysis 
 Cytokine Secretion from NHEK cells during our preliminary experiments was 
analyzed via one way ANOVA with a Bonferroni multiple comparison post test where a 
P value of .0001 or less was considered significant. All recurrent CA-MRSA isolates 
were compared to the MSSA group to determine significance in these experiments. Since 
the cytokine secretion from HaCat cells exhibited a large degree of variability, we 
compared the medians of the CA-MSSA and recurrent CA-MRSA groups and analyzed 
these differences using a Mann Whitney U test for significance in order to account for the 
non-normal distribution of data produced by the use of clinical isolates. A p value of 0.05 
was considered to be statistically significant. When comparing cytokine secretion 
between different bacterial isolates from the same patient, we utilized the means of these 
values from 2 independent experiments and represented these in bar graph form 
indicating the standard error of the mean (SEM). Finally, in analyzing Western Blot data, 
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densitometry values between two independent experiments were averaged and presented 
in bar graph form indicating the SEM. 
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CHAPTER FOUR 
EXPERIMENTAL RESULTS 
 
Cytokine Secretion from NHEK cells post exposure to bacterial culture supernatants 
It is known that S. aureus is most commonly recognized by host TLR2 surface 
receptors that signal through the MyD88 signaling pathway, ultimately leading to 
progression of an inflammatory response. We asked if recurrent CA-MRSA isolates 
secrete a bacterial factor(s) that is able to suppress TLR2-dependent pro-inflammatory 
and anti-inflammatory cytokine secretion from keratinocytes. If recurrent CA-MRSA 
isolates suppress the TLR2 pathway via a secreted bacterial virulence factor(s), this could 
explain the ability of these isolates to result in more severe, and often recurrent, 
infections. In order to assess this possibility, we stimulated normal human epidermal 
keratinocytes (NHEKs) in vitro for 24 hours with three day bacterial culture supernatants 
from recurrent CA-MRSA or non-recurrent MSSA isolates. The downstream cytokine 
secretion from keratinocytes post exposure to either recurrent CA-MRSA or MSSA 
bacterial culture supernatants were measured by ELISA and compared to one another.  
We found that recurrent CA-MRSA bacterial conditioned media exposure 
resulted in a significant decrease in secretion of IL6, IL8, IL10, and TNFα from 
keratinocytes (Figure 3). Keratinocytes exposed to recurrent CA-MRSA bacterial culture 
supernatants exhibited, on average, a fold decrease of 3.9, 6.0, 2.9, and 2.7 in IL6, IL8, 
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IL10, and TNFα secretion, respectively, relative to the cytokine secretion of cells exposed 
to MSSA bacterial culture supernatants. 
Our samples included recurrent CA-MRSA isolates obtained from a variety of 
patients seen at the Loyola University Medical Center and an MSSA lab strain (Sa113). 
Table 1 lists the clinical information known about the patients that each of our isolates 
were obtained from. 
Patient 
Initials 
Recurrence 
Number Date Age Sex Source 
2-15 RS 3 1/4/2012 56 yrs M Left foot 
2-35 SB 5 3/20/2012 40 yrs M Right foot 
2-37 FS 6 3/30/2012 70 yrs M Sinus 
2-44 TB 2 4/15/2012 35 yrs M Ear 
2-57 AA 1 12/9/2011 
10 
months F Left gluteal 
2-45 AM 1 10/2/2011 17 yrs M Right leg 
2-48 DM 2 5/14/2012 
33 
months F Groin 
2-59 DD 1 10/31/2011 65 yrs F Abdominal Abscess 
2-64 RW 2 6/16/2012 20 yrs M Pleural Fluid 
Table 1: Clinical information about the recurrent CA-MRSA isolates used in 
preliminary bacterial culture media experiments. Each of the isolates in the above 
table was used in our bacterial culture supernatant exposure experiments outlined below.  
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Figure 3: Pro-inflammatory and anti-inflammatory cytokine release by 
keratinocytes after treatment with CA-MRSA bacterial culture supernatants as 
shown by ELISA. NHEKs in vitro were treated with a 20% solution of bacterial culture 
supernatants from different recurrent CA-MRSA isolates from different patients (labeled 
with a letter corresponding to each patient) MSSA Sa113, TSB (negative control) or an 
untreated group for comparison. Keratinocytes treated with recurrent CA-MRSA 
bacterial culture supernatants exhibited decreased levels of secreted pro-inflammatory IL-
6, IL-8 and TNFα as well as anti-inflammatory IL-10. *P<.0001 vs. MSSA treatment 
group after one way ANOVA with a Bonferroni multiple comparison post test. 
 
HMGB1 secretion from NHEK cells post exposure to bacterial culture supernatants 
TLR2 is expressed on keratinocytes and is a known receptor for HMGB1. 
HMGB1 binding to TLR2 results in subsequent release and production of pro-
inflammatory and anti-inflammatory cytokines. We then asked if recurrent CA-MRSA 
isolates secrete a bacterial factor(s) that is able to suppress HMGB1 secretion from 
keratinocytes. Therefore, if recurrent CA-MRSA isolates are able to suppress TLR2 
signaling through a secreted factor(s), we would expect the inflammatory effects of 
HMGB1 to be dampened as well. To answer this question, we again stimulated NHEKs 
in vitro for 24 hours with three day bacterial culture supernatants from recurrent CA-
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MRSA or MSSA isolates. HMGB1 secretion from keratinocytes post exposure to either 
recurrent CA-MRSA or MSSA bacterial culture supernatants was measured by ELISA 
and compared to one another. We determined that recurrent CA-MRSA bacterial culture 
supernatant exposure resulted in a significant decrease in HMGB1 secretion from 
NHEKs (Figure 4). Keratinocytes exposed to recurrent CA-MRSA bacterial culture 
supernatants exhibited, on average, a fold decrease of 2.4 in HMGB1 secretion relative to 
the HMGB1 secretion of cells exposed to MSSA bacterial culture supernatants.  
 
Figure 4: HMGB1 secretion measured from NHEKs exposed to MSSA or recurrent 
CA-MRSA bacterial culture supernatants for 24 hours measured by ELISA. 
Decreased levels of secreted HMGB1 were observed in supernatants from keratinocytes 
treated with recurrent CA-MRSA bacterial culture supernatants. HMGB1 levels were 
measured by ELISA and normalized to total protein.*P<.0001 vs. MSSA treatment group 
after one way ANOVA with Bonferroni’s multiple comparison post test. 
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Cytokine secretion from HaCat cells post infection with live bacteria 
Since we demonstrated that recurrent CA-MRSA bacterial culture supernatant 
exposure to keratinocytes was able to suppress cytokine secretion, we wanted to 
determine if cell-cell contact resulted in a similar decrease in downstream TLR2-
mediated cytokine secretion. We then asked if live, recurrent CA-MRSA bacterial 
isolates were also able to suppress downstream TLR2 pro-inflammatory and anti-
inflammatory cytokine production. In order to answer this question, we infected HaCat 
cells with live, recurrent CA-MRSA, non-recurrent CA-MRSA, or non-recurrent CA-
MSSA bacterial isolates for 6 hours and compared relative levels of downstream cytokine 
secretion by ELISA.  
Treatment of keratinocytes with recurrent CA-MRSA isolates resulted in a 
statistically non-significant decrease in pro-inflammatory TNFα and anti-inflammatory 
(IL10) secretion relative to cells treated with either non-recurrent CA-MSSA or non-
recurrent CA-MRSA (Figure 5). Recurrent CA-MRSA isolate infection did result in a 
statistically significant decrease in pro-inflammatory IL8 secretion from keratinocytes 
post infection. A similar cytokine profile was observed with increased total cytokine 
levels at a 10 hour time point (data not shown). The clinical information of the isolates 
used in our live infection experiments are shown in Table 2.  
Patient 
Initials 
Recurrence 
Number Date Age Sex Source 
FS 1 1/24/2011 69 yrs M Right sinus 
  3 7/12/2011 70 yrs M Sinus 
  6 3/30/2012 70 yrs M Sinus 
TK 1 9/23/2011 50 yrs M Left leg 
  4 11/12/2013 52 yrs M Left knee 
CM 1 1/21/2011 84 yrs F Right foot 
  4 8/13/2012 86 yrs F Right arm 
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AB 1 4/8/2011 40 yrs F Right hip 
  4 1/29/2013 42 yrs F Right hip 
SB 1 3/16/2011 39 yrs M Right big toe 
  3 11/23/2011 39 yrs M Right big toe 
  5 3/20/2012 40 yrs M Right foot 
GF 1 11/4/2011 68 yrs F Left arm 
  3 5/31/2012 69 yrs F Catheter drain site 
PB 3 5/19/2011 63 yrs F Abdominal Abscess 
  6 5/31/2013 65 yrs F 
Abdominal wall 
tissue 
Table 2: Clinical information for the recurrent CA-MRSA isolates used in our live 
infection experiments. Each of the isolates in the above table was used to infect HaCat 
cells for 6 hours as outlined below. We selected an isolate from an earlier and a later 
recurrence within each of these randomly selected patients for these studies. 
 
We then compared the effects of recurrent CA-MRSA isolates obtained from the 
first recurrence and those obtained from later recurrent infections of the same patient to 
determine if recurrence correlated with changes in cytokine secretion. Here, any infection 
that occurred at least three months after the initial infection was considered a recurrent 
infection. If exposure to isolates from subsequent CA-MRSA infections results in a 
decrease in pro-inflammatory and/or anti-inflammatory cytokine secretion from 
keratinocytes, this could suggest that these isolates are able to more effectively escape 
recognition by the TLR2 signaling pathway in the skin. We utilized the same live 
infection cell culture system as described above to assess cytokine secretion from 
keratinocytes 6 hours post infection by ELISA. Treatment of keratinocytes with CA-
MRSA isolates from later recurrent infections revealed no statistically significant 
decrease in overall cytokine secretion (Figure 6).  
We additionally looked at keratinocyte cytokine profiles post infection with CA-
MRSA isolates from subsequent infections of the same patient. In some patients (Figure 
7, [panels A-C), recurrent CA-MRSA isolates from later recurrences resulted in a non-
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significant increase in overall IL10 secretion by keratinocytes post infection. In other 
patients (Figure 7, panels D-E), there was an observed non-significant decrease in IL10. 
Levels of TNFα and IL8 secretion from keratinocytes post infection were also not 
significantly different in subsequent infections of the same patient (Figure 7). 
Interestingly, five different non-recurrent CA-MSSA isolates consistently induced a 
similar cytokine secretion profile from keratinocytes post infection (Figure 7, panel F).  
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Figure 5: Relative pro-inflammatory (IL8 and TNFα) and anti-inflammatory (IL10) 
cytokine secretion levels from HaCat cells 6 hours post infection with either non-
recurrent CA-MSSA clinical isolates, recurrent CA-MRSA clinical isolates, a 
vehicle control, or a coagulase negative S. aureus isolate (negative control),  as 
measured by ELISA. There is a trend toward a decrease in cytokine secretion from cells 
treated with recurrent CA-MRSA vs. non-recurrent CA-MSSA isolates. Cytokine ELISA 
values of each isolates were averaged from three independent experiments; each dot 
indicates the average of the cytokine release of HaCat cells treated with a particular 
bacterial isolate. These data were analyzed by comparison of their medians due to the 
large variability and p values were obtained using a Mann Whitney U test as follows: 
IL10 p = 0.4510, TNFα p = 0.2478 and IL8 p = 0.0307. A statistically significant p value 
was designated as 0.05. Statistical significance was only noted in IL8 secretion, though a 
trend toward increased IL10 and TNFα secretion from cells treated with recurrent CA-
MRSA isolates was identified. IL6 was also tested, but levels were very similar to the 
vehicle control in most samples and were therefore are not shown here.  
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Figure 6: Relative pro-inflammatory (IL8 and TNFα) and anti-inflammatory (IL10) 
cytokine secretion levels from HaCat cells 6 hours post infection with recurrent CA-
MRSA clinical isolates as measured by ELISA and grouped by recurrence. When the 
above cytokine data is organized based on the recurrence of the recurrent CA-MRSA 
isolate used to treat HaCat cells in vitro, overall patterns can be identified to predict 
changes in cytokine production that could be contributing to the ability of these isolates 
to cause recurrent infections. Cytokine ELISA values of each isolates were averaged 
from three independent experiments; each dot indicates the average of the cytokine 
release of HaCat cells treated with a particular recurrent CA-MRSA isolate. These data 
were then analyzed by comparison of their medians due to the large variability and p 
values were obtained using a Mann Whitney U test as follows: IL10 p = 0.4351, TNFα p 
= 0.3543 and IL8 p = 0.9433. No significance was noted, though a trend toward increased 
cytokine secretion during later recurrences was identified. 
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Figure 7: Relative pro-inflammatory (IL8 and TNFα) and anti-inflammatory (IL10) 
cytokine secretion levels from HaCat cells 6 hours post infection with subsequent 
CA-MRSA isolates from the same patient during recurrent infections (A-E) or with 
CA-MSSA isolates (F) as measured by ELISA. Differences in the cytokine profiles of 
cells treated with either non-recurrent CA-MSSA or subsequent recurrent CA-MRSA 
bacterial isolates from the same patient can be seen. Panels A-E show the cytokine 
profiles of cells treated with different recurrent CA-MRSA isolates from subsequent 
infections of the same patient. Panel F shows the cytokine profiles of the non-recurrent 
CA-MSSA isolates utilized in our studies. 
 
Total protein expression of surface receptors in HaCat cells post infection with live 
bacteria  
TLR2 is known to require recruitment of and interaction with one of its co-
receptors, most commonly CD14, in order to recognize different lipopeptide structures on 
the surface of pathogens resulting in an innate immune response. Therefore, the next 
question that we asked was whether infection with recurrent CA-MRSA isolates results in 
a decrease in total protein levels of host surface receptors TLR2 and CD14 in 
keratinocytes. If recurrent CA-MRSA isolates decrease the total protein levels of TLR2 
and/or CD14 in HaCat cells post infection, we would expect to see a decrease in pro-
inflammatory (IL8 and TNFα) and anti-inflammatory (IL10) cytokine production in 
response to infection. In order to address this experimental question, we performed total 
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protein Western Blots on whole cell lysates from HaCat cells infected with non-recurrent 
CA-MSSA, non-recurrent CA-MRSA, or recurrent CA-MRSA isolates for 6 hours. These 
blots indicated relatively similar total levels of both TLR2 and CD14 in keratinocytes 
infected with non-recurrent CA-MSSA, non-recurrent CA-MRSA, and recurrent CA-
MRSA isolates (Figure 8). The average densitometry values of each of the above groups 
in two independent experiments were determined and normalized to the loading control, 
β-actin (Figure 8). The medians of the recurrent CA-MRSA treated group were compared 
to the medians of the non-recurrent CA-MSSA and non-recurrent CA-MRSA groups, 
revealing a non-significant change in total TLR2 and CD14 protein expression at 6 hours 
post infection.. 
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Figure 8: Western blot analysis of total HaCat cell lysates 6 hours post infection 
with MSSA isolates or recurrent CA-MRSA isolates with corresponding 
densitometry values normalized to B-actin suggesting relatively stable levels of 
TLR2 and CD14 post infection. Levels of total TLR2 remained relatively unchanged at 
this time point post infection. A dramatic increase in CD14 was also indicated in all 
MSSA (black bars) and recurrent CA-MRSA (gray bars) infected groups when compared 
to the negative control vehicle and coagulase-negative S. aureus treated groups as 
expected under infection conditions, but the levels between the infection groups were 
very similar and not statistically significant. These graphs show results from one 
experiment that was repeated again with similar results. P values were obtained using a 
Mann Whitney U test to compare MSSA and recurrent CA-MRSA treated groups; p 
values were as follows: TLR2 p=0.8438, CD14 p=0.7756. TLR1 was also imaged, but 
the band was very difficult to capture, but also appeared not to vary significantly between 
groups. 
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NFκB activation in HaCat cells post infection 
Activation of the TLR2 signaling pathway ultimately leads to the phosphorylation 
and activation of the transcription factor, NFκB, which then leads to the upregulation of 
genes encoding for chemokines, cytokines, cell adhesion molecules, and AMPs (6). We 
next wanted to assess the ability of recurrent CA-MRSA isolates to inhibit NFκB 
activation via phosphorylation, which is a necessary event leading to downstream TLR2-
mediated cytokine release. To answer this question, we carried out total phospho-NFκB 
Western Blots in order to compare the relative levels of NFκB activation between 
keratinocytes treated with recurrent CA-MRSA and non-recurrent CA-MRSA or CA-
MSSA isolates. Since NFκB activation occurs very rapidly after infection, we assessed 
the total relative levels of NFκB and phospho-NFκB 15 minutes post infection with our 
bacterial isolates. If recurrent CA-MRSA isolates are able to inhibit the phosphorylation 
of NFκB, then we would expect to see a decrease in downstream pro-inflammatory and 
anti-inflammatory cytokine production. We found that keratinocytes infected with 
recurrent CA-MRSA isolates did not exhibit a significant change in the levels of total 
phospho-NFκB at 15 minutes post infection in our system (Figure 9).  
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Figure 9: Western blot analysis of total HaCat cell lysates 15 minutes post infection 
with MSSA isolates or recurrent CA-MRSA isolates with corresponding 
densitometry values normalized to total NFκB. These data (using the mean of the 
normalized densitometry values of two experiments) suggest relatively similar levels of 
NFκB activation post infection. An overall increase in NFκB activation was observed 
when compared to the negative control vehicle and coagulase-negative S. aureus treated 
groups as expected under infection conditions, but these levels were relatively stable 
among treatment groups and not statistically significant. A p value was obtained using a 
Mann Whitney U test to compare CA-MSSA and recurrent CA-MRSA treated groups; 
p=0.8639. 
 
HMGB1 secretion from HaCat cells post infection 
HMGB1 is a danger associated molecular pattern (DAMP) that translocates from 
the nucleus to the extracellular milieu, upon TLR2 stimulation to elicit pro-inflammatory 
effects through NFκB activation. The next question that we investigated was if recurrent 
CA-MRSA isolates inhibit HMGB1 secretion from keratinocytes post infection as a 
mechanism to evade recognition by the host immune response. In order to answer this 
question, we carried out HMGB1 ELISAs on cell culture supernatants 6 hours post 
infection with recurrent CA-MRSA, non-recurrent CA-MRSA, and non-recurrent CA-
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MSSA isolates. If recurrent CA-MRSA isolates inhibit the translocation of HMGB1 from 
the nucleus to the extracellular space, we would expect to see decreased secretion of 
HMGB1 from keratinocytes treated with recurrent CA-MRSA isolates. Infection of 
keratinocytes with recurrent CA-MRSA isolates did not exhibit a significant decrease in 
HMGB1 secretion 6 hours post infection in our system (Figure 10).  
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Figure 10: Relative HMGB1 secretion from HaCat cells 6 hours post infection with 
either non-recurrent CA-MSSA clinical isolates, recurrent CA-MRSA clinical 
isolates, a vehicle control, or a coagulase negative S. aureus isolate (negative 
control),  as measured by ELISA. Stimulation of HaCat cells for 6 hours with live 
bacterial isolates resulted in no significant difference in HMGB1 secretion between CA-
MSSA and recurrent CA-MRSA treated groups, indicating that recurrent CA-MRSA 
bacteria are probably not affecting the secretion of this protein as a mechanism to cause 
decreased inflammatory response and immune avoidance during infection. A p value 
were obtained using a Mann Whitney U test to compare MSSA and recurrent CA-MRSA 
treated groups; p=0.6931. 
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HMGB1 localization in HaCat cells post infection 
The function of HMGB1 is dependent on its location within the cell. Under 
normal conditions HMGB1 acts as a DNA-binding protein and transcription factor in the 
nucleus (1). Under inflammatory conditions, such as IL6 and TNFα production, this 
protein can be translocated from the nucleus to the cytoplasm. In the cytoplasm it is 
packaged into vesicles prior to its secretion into the extracellular space, where it can then 
bind TLR2 (1) in order to amplify the inflammatory response. We then asked if recurrent 
CA-MRSA isolates inhibit the translocation of HMGB1 from the nucleus to the 
cytoplasm, or from the cytoplasm into the extracellular space in keratinocytes post 
infection. In order to answer this question, we carried out ICC assays on keratinocytes 6 
hours post infection with either recurrent CA-MRSA or non-recurrent CA-MSSA isolates 
in order to compare relative levels of HMGB1 localization by utilizing a fluorescently 
conjugated HMGB1 antibody. Similarly, if recurrent CA-MRSA isolates inhibit the 
translocation of HMGB1 from the cytoplasm to the extracellular space, we would expect 
to see increased levels of cytoplasmic HMGB1 in keratinocytes infected with these 
isolates. Unfortunately we were not able to address this question using this method due to 
technical complications. Here, the fluorescent signal due to the bacteria binding the 
fluorescently conjugated secondary antibodies was very high and it was difficult to 
determine localization of HMGB1 in the cells treated with the bacteria groups (Figure 
11).  
47 
 
 
Figure 11: HMGB1 localization via ICC with vehicle treated and CA-MRSA treated 
groups. Here, ICC was carried out using an HMGB1 specific antibody or IgG isotype 
control at 6 hours post infection. The vehicle treated cells show high levels of HMGB1 in 
the nucleus as expected under normal conditions and no staining in the IgG control 
indicating no non-specific binding of the antibody. The CA-MRSA treated group exhibits 
high levels of punctate staining that is localized to the bacteria on the slide and is also 
present a high degree in the IgG control. This FITC signal is so high in the CA-MRSA 
infected cells that I am not able to visualize the cells in the vehicle and infected groups 
under the same microscope conditions, so valid comparisons can not be made between 
groups at this time. Additional troubleshooting will be needed in the future to answer our 
experimental questions regarding localization and co-localization in infected cells with 
immunoassays due to the presence of protein A as discussed previously. 
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CHAPTER FIVE 
DISCUSSION 
Taken together, our data provide some insight into the inflammatory effects of 
different clinical recurrent CA-MRSA and non-recurrent MSSA isolates on keratinocytes 
in vitro. It is important to identify differences in the immune response against these 
pathogens in order to understand why CA-MRSA isolates possess enhanced virulence 
and are often able to cause recurrent infections in otherwise healthy individuals. If 
particular mechanisms underlying the interactions between the bacteria and the host 
immune system are identified, these pathways could serve as targets for improved 
treatment of CA-MRSA infections, particularly those that result in recurrence.  
In all of our analyses we compared the effects of recurrent CA-MRSA isolates on 
keratinocytes to the effects of non-recurrent CA-MSSA isolates under the same 
experimental conditions. Non-recurrent CA-MSSA isolates were the appropriate 
comparison to recurrent CA-MRSA isolates because of their evolutionary background. 
CA-MRSA is thought to have emerged from CA-MSSA, as opposed to HA-MRSA, due 
to the sizes of their SCCmec cassettes (24). Therefore, making a comparison between 
recurrent CA-MRSA and non-recurrent HA-MRSA would be potentially misleading in 
our mechanistic analyses but could be pursued in later phases of this project. 
Additionally, in later experiments, we included a few non-recurrent CA-MRSA bacterial 
isolates in our analysis and determined that there appears to be similar variability and 
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patterns in cells treated with these isolates. The sample size for these isolates was very 
small with only three isolates and could be pursued on a larger scale in the future. 
 
Exposure of keratinocytes to recurrent CA-MRSA bacterial culture supernatants 
TLR2 is known to be the main recognition receptor of S. aureus, therefore, it is 
reasonable to speculate that CA-MRSA is able to cause recurrent infections by 
circumventing TLR2 recognition and signaling. Differences are known to exist between 
the production of secreted virulence factors, such as superantigens, by CA-MRSA and 
CA-MSSA (26). In our initial preliminary experiments, we grew up different recurrent, 
clinical CA-MRSA isolates and an MSSA (Sa113) isolate in culture for three days prior 
to collecting the culture supernatants. These supernatants included any factors that the 
bacteria secreted in the three day time frame as well as any shed cell wall components. 
We demonstrated that exposure of NHEKs to recurrent CA-MRSA bacterial culture 
supernatants resulted in a significant decrease in secretion of pro-inflammatory (IL8, IL6 
and TNFα) and anti-inflammatory (IL10) cytokines post infection. Additionally, we saw 
an increase in total levels of HMGB1 and a decrease in the secretion of HMGB1. These 
findings suggested that a secreted or shed cell wall component(s) produced by recurrent 
CA-MRSA isolates was able to decrease the innate immune response in the skin to a 
greater degree than the MSSA isolate tested. These effects could have been mediated by a 
cell wall component(s) such as lipoteichoic acid, or by a secreted virulence factor(s) 
produced by the bacteria at some point during the three day time course. 
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One possible explanation for the observed decrease in presumed TLR2-mediated 
cytokine secretion from keratinocytes after exposure to recurrent CA-MRSA bacterial 
culture supernatants, is the secreted S. aureus virulence factor staphylococcal 
superantigen-like protein 3 (SSL3) (36). This family of staphylococcal superantigen-like 
proteins is becoming of increasing interest due to their described ability to mediate 
immune evasion. SSL3 is able to specifically bind the extracellular domain of TLR2 on 
neutrophils and monocytes in mice leading to a reduction of downstream cytokine 
production (36). Since keratinocytes are also known to express TLR2, we hypothesize 
that this virulence factor is upregulated by recurrent CA-MRSA isolates. This would also 
explain why we were unable to reproduce the decrease in TLR2-mediated cytokine 
secretion by keratinocytes in our live infection model as the bacteria were washed prior to 
infection, removing any secreted factors that they may have produced. Additionally, the 
six hour infection that was utilized would possibly not have been enough time to produce 
enough of this virulence factor to cause a noticeable effect in downstream TLR2 
signaling in our system. 
It has also been shown that bacterial culture supernatants of the Staphylococcus 
epidermidis, were able to activate TLR2 signaling resulting in an increase in the 
production of AMPs and increased defense against infection (74). This study further 
highlights the possibility that secreted virulence factors, even of commensal species, are 
able to affect host signaling pathways. It also showcases a limitation of our cell culture 
model. In our model, we do not have the effects of other bacteria, including commensals, 
which could also be playing a role in the establishment of recurrent infection.  
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Heterogeneity in the effects of live infection of keratinocytes with recurrent CA-MRSA 
isolates in vitro 
We speculated that cell-cell contact between recurrent CA-MRSA isolates and 
keratinocytes may also be involved in the observed suppression of the inflammatory 
response, acting as a possible contributing factor in the pathogenesis of recurrent CA-
MRSA infection. An in vitro model using the immortalized HaCat cell line was utilized 
to allow us to asses the ability of recurrent CA-MRSA isolates to suppress TLR2-
mediated pro-inflammatory cytokine secretion from keratinocytes during infection. Our 
data suggested that there was a large degree of heterogeneity in downstream TLR2 
inflammatory events in cells treated with recurrent CA-MRSA and non-recurrent CA-
MSSA isolates in keratinocytes.  
The observed decreases in relative levels of cytokine secretion, surface receptor 
expression, or NFκB activation were likely not statistically significant due to the large 
biological heterogeneity in the inflammatory response post infection between individual 
isolates. We knew very little clinical information about the patients that our isolates were 
obtained from. There are a number of host and environmental factors that could have 
affected the bacteria isolated. These include the severity of the infection at the time of 
bacterial isolation, if the patient was on a current or recent antibiotic regimen, or even the 
genetic dispositions or other comorbidities of these patients. All of these factors have the 
potential to influence the environment in which the bacteria are adapting and could affect 
their overall physiology and pathogenicity. Additionally, the isolates that we investigated 
were not strain typed so it was unclear if the same bacterial strain is the one that is 
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responsible for recurrent infections or if they are different strains. This is something that 
should be investigated in the future to better understand if recurrent infections are due to 
the adaptation of the bacteria or if they are due to host factors.  
Another recent study utilized human embryonic kidney (HEK) cells transfected 
with TLR2 activity in order to assess the ability of different clinical S. aureus isolates to 
stimulate TLR2. Here, IL8 cytokine production was used as a readout of TLR2 activation 
24 hours post infection (46). This experimental set up was similar to ours and these 
investigators also identified a large degree of heterogeneity in the TLR2 activity 
exhibited by different S. aureus isolates as we observed in our studies. These 
investigators also compared TLR2 activation post infection of HEK cells with isolates 
obtained from patients with either cystic fibrosis or invasive disease. They found no 
correlation between the origin of the isolate and the TLR2 activity (46). Our findings 
extend these observations in that we observed a similar pattern in keratinocytes 
stimulated with clinical non-recurrent CA-MSSA or recurrent CA-MRSA isolates for 6 
hours. Additionally, these investigators looked at a variety of cellular processes to 
discover which one(s) were responsible for these changes in TLR2 activity. They 
discovered that this activity appears to be due to a variety of factors including 
proliferative activity, capsule formation, protein synthesis and cell wall factors (46). 
 
HMGB1 function during recurrent CA-MRSA infection 
It is known that mammalian cells do not produce new pools of HMGB1 until 
about 16 hours post stimulation (27). The HMGB1 utilized and secreted by the cell prior 
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to this time point is from a preformed nuclear store of this protein (27). Therefore, we 
would not expect to see any changes in the total HMGB1 levels, which we observed in 
our system via Western Blot (data not shown). We were unfortunately limited with our 
cell culture model in terms of the amount of time that we could expose our cells to the 
live bacteria in culture prior to killing the cells. Importantly, we were still able to assess 
the secretion of HMGB1 into the extracellular space post infection. This allowed us to 
determine that recurrent CA-MRSA isolates do not suppress the secretion of HMGB1 
from keratinocytes post infection relative to the levels of HMGB1 secretion from non-
recurrent CA-MSSA treated groups. This indicated that there was not a variation in the 
amount of HMGB1 in the extracellular space available to interact with TLR2 at the cell 
surface that could stimulate the TLR2 signaling pathway. Since recurrent CA-MRSA 
isolates did not result in a significant decrease in pro and anti-inflammatory cytokine 
secretion from keratinocytes post live infection, we did not carry out the initially 
proposed addition of exogenous HMGB1 experiments. Therefore, HMGB1 secretion was 
not affected by recurrent CA-MRSA cell surface virulence factors leading to recurrent 
infections under our experimental conditions. Although, HMGB1 secretion was 
decreased after exposure to secreted factors from recurrent CA-MRSA isolates. Due to 
these findings, it is possible that a secreted virulence factor(s), as opposed to a cell 
surface virulence factor, may be responsible for the ability of these bacteria to cause 
recurrent infections in otherwise healthy individuals. 
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Limitations of our in vitro keratinocyte infection model 
There were a number of limitations in our live infection cell culture model. We 
were limited in the amount of time that we could expose the cells to the live bacteria. We 
chose the 6 hour time point after performing an LDH cytotoxicity assay (data not shown). 
Cell death was assessed at different time points 2-24 hours post infection and revealed 
that after 8 hours, there was increased cell death and cellular morphology changes in 
keratinocytes infected with live bacteria. We also based our time point on a study looking 
at the kinetics of cytokine production after LPS stimulation of human whole blood (25). 
This study determined that TNFα protein production peaked about 4-6 hours post 
infection before stabilizing and that IL8 protein increased initially up to about 6 to 12 
hours post stimulation (25). Though this was a very different system than ours, it was a 
helpful starting point to determine when we would be able to see changes in protein 
expression in our cells post infection. It has also been found that peak cytokine responses 
post infection of cells with Gram positive bacteria occurs 50 to 75 hours after the 
challenge, as opposed to 1 to 5 hours after a Gram negative challenge (57). This means 
that we may have needed to expose our cells to the live bacteria for much longer than 6 
hours to see changes in the response of the keratinocytes post infection. A possible way 
to address this limitation in the future could be by using heat killed bacteria so that their 
cell wall components would still be exposed to the cells. Here, the bacteria would not be 
dividing and invading cells so the cytokine profiles could be examined for longer periods 
of time. The problem with this method is that if the bacteria are not growing and dividing, 
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then infection conditions are not being replicated which could lead to a different immune 
response by the host cells. 
Our system was also limited to looking at the effects of CA-MRSA isolates on 
keratinocytes alone and vice versa. It is also likely that there are other confounding 
factors that my influence these interactions in vivo and with the contributions of other 
immune cells and cellular processes. Additionally, the cytokine secretion profiles that we 
investigated would directly and indirectly affect the recruitment and activity of other 
immune cell types. For example, IL10 and TNFα have been shown to play bilateral roles 
during injury and infection (11). IL10 is an anti-inflammatory cytokine that skews the 
immune response toward a Th2 response by promoting B cell survival and proliferation. 
TNFα is a pro-inflammatory cytokine that is known to activate macrophages. And finally, 
IL8 is another pro-inflammatory cytokine that is produced in response to infection and 
plays a role in neutrophil activation and recruitment to sites of infection. Therefore, the 
production of these cytokines is only one aspect of the host immune response to infection 
that could be affected by recurrent CA-MRSA virulence factors. 
 
The challenge of live bacterial infection in vitro 
Working with live bacteria posed a number of problems in regards to our assays 
and much troubleshooting was done to try to overcome these obstacles. It is important to 
note some of these challenges in order to address them more effectively in future studies 
in the field.  
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The largest problem was trying to find ways to overcome the antibody binding 
activity of the S. aureus virulence factor, Protein A. Since we infected cells with S. 
aureus bacteria for 6 hours prior to collection, the cells contained bacteria that were 
internalized during the incubation period. Protein A is a virulence factor secreted by S. 
aureus that binds the Fc portion of immunoglobulin molecules to prevent opsonization 
and antibody recognition of the pathogen (6). This protein was a problem when trying to 
carry out the initially proposed co-immunoprecipitation experiments to assess for protein-
protein interactions between TLR2 and its co-receptors. The protein A that was contained 
in the bacteria used in the assay was presumably leading to nonspecific binding of the 
antibodies utilized. We saw heavy bands appearing around 50 kD and 25 kD (data not 
shown) which we presume were showing up where the antibodies were recognizing the 
heavy and light chains of the TLR2 antibody used in the pull down. This problem would 
have prevented us from visualizing CD14 and HMGB1 via co-immunoprecipitation due 
to their molecular weights that are close to that of the heavy chain (~50 kD).  
To solve this problem, we tried to utilize protein G beads (as opposed to protein 
A/G beads) for the Co-IP experiments but we were still detecting the problematic bands 
as encountered previously. The likely reason for this was that after complete cell lysis, 
protein A was present in high amounts and able to bind the Fc regions of any IgG 
molecules, including the Rabbit IgG used in the pre-clear step, the primary antibodies, 
and the secondary antibodies. During the pre-clearance step we did add a large amount of 
normal rabbit IgG to remove any non-specific binding and to allow for the removal of 
protein A from our samples. It is likely that this did not remove all protein A from the 
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sample. The protein A that remained would then be able to competitively bind with the 
primary antibody and lead to decreased efficiency of the pull down of the protein of 
interest. This additionally results in the pull down of protein A and therefore, a large 
amount of the primary antibody along with it, which are then visualized on the Western 
Blot downstream. We used an easy blot secondary antibody (Genetex, Ca. No. 
GTX221666-01) that only recognizes non-reduced antibodies and should not detect bands 
due to the heavy and light chains. Unfortunately, the protein A can also bind the 
secondary antibody non-specifically resulting in visualization of the IgG heavy and light  
chain bands by Western blot. This was also likely the reason why using a primary 
antibody from a different species also resulted in bands where we would expect the heavy 
and light chains, since protein A does not differentiate between species of IgG. This 
problem is likely not encountered in straight Western Blot assays, because the amount of 
protein A with all of the other proteins present in the sample is minute, while in the Co-IP 
protocol, these lysates are concentrated. 
With these considerations and experiences in mind, and in the interest of time, we 
decided to use an ICC protocol that was well established in the lab to look at the co-
localization of TLR2 and its co-receptors. This method does not give a direct indication 
of protein-protein interactions but instead provides strong evidence for co-localization 
between TLR2 and its co-receptors, which is required prior to TLR2 activation. 
Unfortunately, this assay posed its own challenges as well. In the ICC protocol, the cells 
that were infected with the bacteria were binding to the fluorescent antibodies and 
producing non-specific florescent staining (Figure 11). This non-specific staining was 
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slightly improved by changing the blocking reagent to a solution of 10% heat inactivated 
FBS, as opposed to the superblock reagent (Scytek Laboratories, Cat. No. AAA125), but 
this did not solve the problem. This was likely due to the large amounts of bacteria that 
remained on the slides even after additional wash steps. Increasing the FBS concentration 
and/or blocking time (>30 minutes) may further solve this problem, but it should be noted 
that we are not aware of any higher concentrations of FBS being used in assays such as 
these. It might be beneficial to test varying concentrations of FBS on the efficiency of the 
block while also being careful not to over saturate the system with antibodies. Also, a 
number of our antibodies that we purchased for use in these experiments did not work 
well in HaCat cells under out experimental conditions with either acetone or 
paraformaldehyde fixation. We could not visualize any staining by some of these 
antibodies on our Evos microscope. We did try to use deconvolution microscopy to 
determine if the signal produced by these antibodies was just very low due to the 
conditions in my system, or if the antibodies were not binding appropriately to the cells. 
This method utilizes a number of mathematical algorithms to analyze images from 
different focal planes and combines them to form a clearer three dimensional image (67). 
After doing this, we were still unable to see any florescent signal except for the signal 
that was due to the bacteria binding the secondary antibody (data not shown). The co-
localization of CD14 and TLR2 in human monocytes after LTA exposure has been 
demonstrated successfully with the use of confocal microscopy (75). Additionally, TLR2 
has been imaged by ICC successfully in murine keratinocytes using confocal microscopy 
(76). The success of these experiments indicate that trying different imaging techniques 
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may also be required to assess co-localization between TLR2 and its co-receptors and 
should be further pursued in the future. 
 
Future directions 
This project was the first to try to answer the question of how CA-MRSA isolates 
are able to cause recurrent infections. Therefore, there are still a number of unanswered 
questions and future directions that could be pursued.  
The co-localization of TLR2 and its co-receptors is still a very important question 
that should be addressed, but under our experimental conditions, it was difficult to 
overcome the problem of protein A activity in our samples. Therefore, the 
troubleshooting mentioned above should be pursued in order to assess these interactions. 
Additionally, it has come to our attention that HaCat cells do not express TLR6 (28), 
while primary skin cells do, so determining the interaction of TLR2 with this co-receptor 
was removed from our experimental methods. HaCat cells are an immortalized cell line 
and have variable expression of particular TLRs when compared to NHEKs and the 
human epidermis (28). Therefore, in the future, these processes should be further 
investigated in an in vitro model using NHEKs or an ex vivo skin infection model using 
human epidermis samples to further establish the clinical relevance of our findings. 
We have been unable to successfully separate nuclear and cytosolic extracts from 
HaCat cells. This is possibly due to the large size and high protein content of these cells 
(at least 5x more protein content than primary cells). We attempted to grow the cells up 
in increasingly smaller cell culture dishes with increasing efficiency, but have still not 
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been able to completely separate these extracts.  Due to this, we were only able to assess 
the total levels of phospho-NFκB, NFκB, and HMGB1 and were not able to look at the 
cellular compartmentalization of these molecules. Looking at these total levels still 
provided us with valuable information on if recurrent CA-MRSA isolates could decrease 
the levels of NFκB activation as hypothesized. An alternative approach to look at 
localization of NFκB in the future with total protein lysates, could be to probe total 
protein Western Blots with an antibody against IκB, the inhibitor protein that keeps 
NFκB in the cytoplasm. Upon phosphorylation of this protein, a nuclear localization 
signal on NFκB is exposed and it is transported into the nucleus and the IκB protein is 
tagged for degradation by the proteosome. Looking at the levels of phospho-IκB, as 
compared to total levels of IκB, in total protein lysates could help to determine the 
amount of nuclear NFκB indirectly.  Though, based on our results, it does not appear that 
NFκB translocation is effected in our assay due to the relatively stable levels of total P-
NFκB present, which requires NFκB to get into the nucleus prior to phosphorylation and 
activation. Additionally, troubleshooting experiments should be continued to determine 
the best protocol to separate the nuclear and cytosolic extracts of these samples in order 
to directly determine the localization of these molecules post infection in keratinocytes. 
In our ICC experiments, though the cells stained well in the vehicle control, it was 
difficult to analyze the infection and vehicle groups with the same microscope settings 
due to the differences in light intensity. Even with appropriate antibodies this would still 
be a problem with any ICC experiments that utilize our experimental conditions with live 
bacteria. Potentially in the future, the concentration of bacteria could be decreased to 
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improve this problem. Additionally, confocal microscopy may be able to be used with 
more appropriate antibodies to solve this problem. This method allows you focus more 
closely and clearly on a smaller area of your slide that might allow for the avoidance of 
the signal due to the bacteria binding the antibodies in the assay (80). Of note, it was 
difficult to separate what was true staining of the cells and what staining was caused by 
the bacteria in this assay. It may be useful to use a structural stain as well for these assays 
to be able to visualize the boundaries of the cells instead of just the nucleus. 
In the interest of time, I was not able to perform the propposed CHiP assays. In a 
future project, the CHiP assays would give a good indication of possible changes at the 
gene level, as opposed to the protein level where the rest of our experiments are focused. 
Of note, since the binding of HMGB1 is known to be non-specific and low affinity, it 
may be difficult to capture this binding interaction in a ChIP assay. Another possible 
complication is the time frame of these experiments. We have proposed to look at a 6  
hour time point, but it is also possible that these transcriptional changes could occur at 
various time points during infection. 
And finally, we believe that it would also be beneficial to further investigate the 
effects of the secreted factors on TLR2-mediated cytokine secretion from keratinocytes 
post infection as that is where we were able to see the most notable difference between 
non-recurrent CA-MSSA and recurrent CA-MRSA treated groups. If these studies are to 
be carried out, they should be done with additional MSSA isolates to make sure that the 
findings still hold true when using clinical CA-MSSA isolates, as opposed to a lab MSSA 
strain (Sa113). Additionally, these studies could be extended to a larger number of 
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samples. Due to the large variability within our samples, this would be a good idea in 
order to determine the clinical relevance of these findings. It would also be beneficial to 
use a TLR2 neutralizing antibody to determine if these effects are in fact mediated by 
TLR2, as opposed to some other recognition receptor in keratinocytes such as RAGE or 
TLR4. Due to the above mentioned cell culture model limitations, it is very important to 
develop ex vivo and in vitro models to further these findings. All of these experiments 
would allow us to better understand the interactions between recurrent CA-MRSA 
isolates and keratinocytes and would potentially allow for creation of better 
immunomodulatory treatments for recurrent CA-MRSA infections in the clinic.  
 
Summary and conclusions 
In conclusion, the goal of this project was to better understand how recurrent CA-
MRSA bacterial isolates are able to establish recurrent infections in otherwise healthy 
individuals. It was hypothesized that this was possible due to the production of a cell-
surface virulence factor by these isolates that circumvented the TLR2 recognition 
signaling pathway in keratinocytes. We found that exposure of keratinocytes to bacterial 
culture supernatants from recurrent CA-MRSA isolates resulted in significantly 
decreased secretion of  pro-inflammatory (IL6 and TNFα) and anti-inflammatory (IL10) 
cytokines.  We further demonstrated that live keratinocyte infection with recurrent CA-
MRSA isolates did not significantly alter the production of these cytokines. We also 
identified no significant difference in cytokine secretion from keratinocytes treated with 
CA-MRSA isolates from subsequent infections of the same patient. Finally, we 
63 
 
determined that recurrent CA-MRSA isolates did not decrease NFκB activation, total 
TLR2 or CD14 protein levels, or HMGB1 secretion under our experimental conditions. 
Our hypothesis suggesting that recurrent CA-MRSA cell surface virulence factors 
were responsible for the decreased recognition by TLR2 host receptors proved to be 
incorrect. Our findings suggest that a secreted virulence factor(s) may responsible for the 
observed suppression of the inflammatory responses in keratinocytes post infection with 
recurrent CA-MRSA isolates. These findings have important implications in the clinic 
and in how physicians currently manage recurrent CA-MRSA infection. 
The next steps should be to further determine the involvement of particular 
secreted virulence factor(s) in order to potentially use it as a target for further 
immunotherapies of recurrent CA-MRSA. As previously mentioned, a promising starting 
point to these analyses is the further investigation of the SSL3 protein and its expression 
during recurrent CA-MRSA infections. This protein was discovered relatively recently so 
there are no commercial antibodies or PCR probes against this antigen. This means that 
future work could be done in developing these tools for use in immunoassays in order to 
determine if SSL3 may be playing a role in the ability of CA-MRSA to cause recurrent 
infections. Based on our findings, we hypothesize that recurrent CA-MRSA isolates 
upregulate SSL3 expression resulting in a decrease in TLR2-mediated cytokine secretion 
from keratinocytes and therefore, decreased recognition of the pathogen in the skin. 
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